Summit Therapeutics PLC (SMMT) Shares Outstanding 2006–TTM

Name: Summit Therapeutics PLC (SMMT) shares outstanding history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-07-25

Summit Therapeutics PLC annual shares outstanding for fiscal TTM was 778 million shares, an increase of 4.0% from 748 million shares in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

SMMT Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Shares Outstanding (M)	778M	748M	719M	620M	193M	92M	70M	33M	86M	65M	62M	59M	40M	21M	—	178M	38M	67M	53M	48M	36M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMMT Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Shares Outstanding (M)	778M	775M	766M	744M	743M	738M	738M	727M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

JAZZ Shares Outstanding — Jazz Pharmaceuticals PLC
ASND Shares Outstanding — Ascendis Pharma AS
EXEL Shares Outstanding — Exelixis Inc
BBIO Shares Outstanding — BridgeBio Pharma Inc
HALO Shares Outstanding — Halozyme Therapeutics Inc
BMRN Shares Outstanding — Biomarin Pharmaceutical Inc

More SMMT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All SMMT financial statements → Interactive SMMT charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.